Mallinckrodt
Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. The company's areas of focus include autoimmune diseases, neurology, and pain management.
History[edit | edit source]
Mallinckrodt was founded in 1867 in St. Louis, Missouri, by three brothers: Gustav, Otto and Edward Mallinckrodt. The company initially produced chemicals for photography, but soon expanded into other areas, including pharmaceuticals.
In the 1950s, Mallinckrodt became a key player in the nuclear medicine field, supplying radiochemicals for medical use. In the following decades, the company continued to expand its product portfolio and global presence.
In 1982, Mallinckrodt was acquired by International Minerals and Chemical Corporation (IMC) and became a part of the newly formed IMCERA Group. In 1996, Mallinckrodt was spun off as a separate company and listed on the New York Stock Exchange.
In recent years, Mallinckrodt has focused on developing and commercializing innovative therapies for patients with severe and critical conditions. The company's leading products include Acthar Gel, a treatment for multiple sclerosis, and Inomax, a treatment for newborns with respiratory failure.
Products and Therapies[edit | edit source]
Mallinckrodt's product portfolio is focused on specialty pharmaceuticals. The company's leading product, Acthar Gel, is used to treat a variety of autoimmune and inflammatory conditions, including multiple sclerosis, lupus, and rheumatoid arthritis. Inomax, another key product, is used to treat newborns with hypoxic respiratory failure.
In addition to these products, Mallinckrodt also offers a range of other therapies for conditions such as nephrotic syndrome, hepatorenal syndrome, and pulmonary hypertension.
Research and Development[edit | edit source]
Mallinckrodt is committed to advancing the field of specialty pharmaceuticals through ongoing research and development. The company's R&D efforts are focused on developing new therapies for unmet medical needs, improving existing products, and exploring new applications for its current therapies.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
